THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare ...

Lexicon Pharmaceuticals is a biopharmaceutical company that uses a unique approach to gene science to develop treatments for people with serious and life-threatening conditions. The company's ...

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...

THE WOODLANDS, Texas - Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX), a biopharmaceutical company, announced today a significant restructuring plan that includes the elimination of its commercial ...

Lexicon reported a net loss of $53.4 million in Q2 2024, with revenues of $1.6 million, primarily from sales of INPEFA, the marketed form of sotagliflozin. The company is also preparing for an FDA ...

Lexicon Fabricators and Constructors is expanding operations and adding 130 employees with the purchase of a north Louisiana steel producer. The Little Rock company announced Tuesday that it has ...

Lexicon Fabricators and Constructors is expanding operations and adding 130 employees with the purchase of a north Louisiana steel producer. The Little Rock company announced Tuesday that it has ...